At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Not Yet Opened 08-03 16:00:00 EDT
24.97
+1.58
+6.73%
盘后24.97
+0.000.00%
19:34 EDT
High26.62Low23.50Vol54.41K
Open23.51D1 Closing23.39Amplitude13.32%
Mkt Cap24.41MTradable Cap21.92MTotal Shares977.97K
T/O1.39MT/O Rate6.20%Tradable Shares878.20K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing
THOMSON REUTERS  ·  08-01
Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing
Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle
Reuters  ·  08-01
Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle
Quince Therapeutics Announces Special Shareholder Meeting
Reuters  ·  08-01
Quince Therapeutics Announces Special Shareholder Meeting
Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing
THOMSON REUTERS  ·  08-01
Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)
TIPRANKS  ·  07-31
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)
Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82
THOMSON REUTERS  ·  07-29
Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82
Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board
Reuters  ·  06-30
Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
THOMSON REUTERS  ·  06-30
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts
TIPRANKS  ·  06-27
Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts
Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description
Reuters  ·  06-27
Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description
Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts
Reuters  ·  06-12
Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts
Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100
Reuters  ·  06-12
Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100
Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Reuters  ·  05-22
Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Quince Therapeutics announces LAM-001 data
TIPRANKS  ·  05-18
Quince Therapeutics announces LAM-001 data
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
TIPRANKS  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
Quince Therapeutics prices private placement raising up to $187 million
Reuters  ·  05-18
Quince Therapeutics prices private placement raising up to $187 million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Reuters  ·  05-18
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Reuters  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
THOMSON REUTERS  ·  05-18
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients
Reuters  ·  05-18
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients

Introduction

Company Name.
Quince Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--